Cogent Biosciences, Inc. (COGT) AI Stock Analysis

Cogent Biosciences, Inc. is a biotechnology firm dedicated to advancing precision therapies tailored for genetically defined diseases. At the forefront of its pipeline is CGT9486, a selective tyrosine kinase inhibitor crafted to target the KIT D816V mutation responsible for driving systemic mastocytosis, as well as other mutations within KIT exon 17 prevalent in advanced gastrointestinal stromal tumors. In collaboration with Plexxikon Inc., the company entered a strategic licensing agreement to accelerate the research, development, and commercialization of bezuclastinib. Headquartered in Cambridge, Massachusetts, the firm was founded in 2014 and was previously known as Unum Therapeutics Inc. before rebranding in October 2020.

Cogent reported annual revenue of $6.4M in FY2016, which rose 31.5% to $8.4M in FY2017 and 16.4% to $9.7M in FY2018. FY2019 revenue expanded 131.1% to $22.5M before contracting 65.0% to $7.9M in FY2020, resulting in a 5-year revenue CAGR of 21.4% from FY2015 to FY2020. Operating margins remained deeply negative throughout, declining from -300.1% in FY2016 to -1044.3% in FY2020 as R&D expense increased to $72.6M. Net income fell from -$18.1M in FY2016 to -$74.8M in FY2020. For the trailing twelve months ended June 30, 2026, revenue was $0, with quarterly revenue down 100.0% year-over-year and EPS at -$2.16.

As of June 30, 2026, Cogent Biosciences held $792.3M in cash and short-term investments alongside total debt of $244.3M, yielding a net cash position of $548.0M. Total assets stood at $834.5M against shareholders' equity of $532.4M. The company shows strong balance sheet liquidity with a current ratio of 13.57 and a debt-to-equity ratio of 0.46. Capital expenditures were $1.6M in FY2025, while operating cash flow in FY2020 was -$35.9M and the 5-year share count increased 290.4%.

Cogent Biosciences carries a market capitalization of $5.12B and an enterprise value of $4.97B. The stock trades at a price-to-sales ratio of 861.2x, substantially above the 4.1x median of its US-listed Healthcare peers, and an enterprise value-to-revenue ratio of 929.3x. Over the past year, COGT returned 80.4%, significantly outpacing the S&P 500 (SPY) return of 16.8%. Over a 5-year timeframe, the stock gained 219.5% versus 83.0% for the S&P 500. However, the stock is down 16.9% year-to-date and sits 17.8% below its 200-day moving average.

Wall Street analysts hold a constructive view on COGT, with 9 Strong Buy, 2 Buy, and 1 Hold ratings, and no Sell or Strong Sell recommendations. The consensus mean price target is $55.82, representing an 89.1% upside relative to the last close of $29.52. For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$2.21 on revenue of $6.0M. For the next fiscal year, 8 analysts model revenue to surge 4637.4% to $283.7M with EPS improving to -$1.18. Cogent has beaten EPS estimates in 2 of the last 4 quarters, with its next earnings date scheduled for November 6, 2026.

This page is an AI-written research summary of Cogent Biosciences, Inc. (COGT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: COGT income statement, COGT balance sheet, COGT key metrics, COGT analyst forecast, COGT chart. See the COGT stock overview for the latest quote and news.